Skip to content
naulon
Not checkedNot checked for notices yet.

The use of heterocyclic-based azo compounds bearing pyrrolidine, imidazole, triazole, and thiazole moieties for the treatment of neglected tropical disease caused by Schistosoma mansoni

Cauê Benito Scarim, Chung Man Chin

European Journal of Medicinal Chemistry Reports · 2021

doi:10.1016/j.ejmcr.2021.100001 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Schistosomiasis (e.g. Schistosoma mansoni) is a neglected tropical disease caused by parasitic worms. It can advance from an acute (juvenile form) to chronic stage (adult form). Single-dose praziquantel (PZQ) is the only therapeutic drug option for adult schistosomiasis (SM) treatment, while its inability to efficiently inhibit earlier larval stages. Its use does not eliminate risks regarding the formation of resistant worms. Thus, new drug candidates to treat SM are urgently needed. Acting as molecule scaffolds, heterocyclic-based azo compounds have shown potential in the treatment of various diseases, including SM. This review article examines several medicinal chemistry-related studies involving these pharmacophore classes (pyrrolidine, imidazole, triazole, and thiazole) from 2011 to 2021, with a focus on SM. Our aim is to facilitate the drug design of novel molecules by optimizing anthelmintic conjugates.

Abstract licence: CC BY-NC

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.